Parker Waichman LLP

Merck’s Januvia Sales Drop

  Merck’s Januvia Drop in Quarterly Sales. Drug maker Merck & Co. Inc. just reported an unexpected drop in the quarterly sales of its Type II diabetes drug Januvia. Januvia is Merck’s fastest- and greatest-selling product since it was approved in 2006. It is the one product that often drives the drug maker’s quarterly earnings, […]

Merck’s Januvia Sales

 

Merck’s Januvia Drop in Quarterly Sales. Drug maker Merck & Co. Inc. just reported an unexpected drop in the quarterly sales of its Type II diabetes drug Januvia.

Januvia is Merck’s fastest- and greatest-selling product since it was approved in 2006. It is the one product that often drives the drug maker’s quarterly earnings, according to a Reuters report. But that has not been the case recently.

Merck’s shares fell 1.6 percent in the face of investor concern about slower Januvia growth. “This was an inflection point for Januvia,” Morningstar analyst Damien Conover told Reuters. “The drug is maturing and will see significant but slower growth over the next few years as the market gets more competitive.” Januvia sales fell 4 percent to $884 million.

Januvia is one of a number of diabetes medicines under investigation by the U.S. Food and Drug Administration (FDA) over links to pancreatic cancer.

Diabetes drugs manufactured by Merck & Company Inc., AstraZeneca PLC, and other drug makers are involved in claims that the medications, when compared to other diabetes drugs, are 25 times likelier to increase pancreatic cancer rates, according to a prior Law360 report. Watchdog group the Institute for Safe Medication Practices (ISMP) reviewed a year of adverse event reports made to the FDA related to five Type 2 diabetes medications, including Merck’s Januvia; Byetta, manufactured by AstraZeneca and Bristol-Myers Squibb Co.; and Tradjenta, made by Eli Lilly & Co.

According to the research, 105 cases of pancreatic cancer were reported

According to the research, 105 cases of pancreatic cancer were reported in patients taking these drugs compared to two cases of patients being treated with drugs from a different class of diabetes medication.

This March, the FDA initiated a probe based on a medical journal study that found that the drugs, known as incretin mimetics, may lead to increased risks for pancreatitis, as well as precancerous cellular changes known as pancreatic duct metaplasia, said Law360. The European Medicines Agency (EMA), Europe’s top drug watchdog group, implemented its own recommendation following the FDA’s probe.

Incretin mimetic drugs include Byetta and Bydureon (exenatide); Victoza (liraglutide); Januvia, Janumet, Janumet XR, and Juvisync (sitagliptin); Onglyza and Kombiglyze XR (saxagliptin); Nesina, Kazano, and Oseni (alogliptin); and Tradjenta and Jentadueto (linagliptin). Incretin mimetics increase certain natural substances that lower raised blood sugar levels.

Diabetics either have abnormally low insulin levels or their bodies are unable to utilize insulin efficiently. Incretin mimetics imitate the body’s incretin hormones, which are supposed to stimulate insulin release following meal consumption. These hormones are also typically used in collaboration with diet and exercise to lower blood sugar in adults diagnosed with Type 2 diabetes.

risk factor for pancreatic cancer

In 2009, the FDA required a label update on these drugs that warned of the risk of acute pancreatitis, a painful, potentially fatal disorder and a known risk factor for pancreatic cancer. Pancreatitis is an inflammation of the pancreas linked to cancer and kidney failure. Chronic pancreatitis is painful, potentially fatal, and a known risk factor for pancreatic cancer.

Merck is the focus of a wrongful death lawsuit being heard in Illinois state court; it alleges that three people developed pancreatic cancer from taking Januvia. The plaintiffs claim that Januvia is defectively designed and lacks adequate warnings about its alleged association with a significantly increased risk of developing pancreatic cancer, said Law360.

Prior research revealed that Januvia and Byetta have been associated with reports of increased risks for pancreatic and thyroid cancers. Another new study also found that the drugs may double patients’ risks for developing pancreatitis, the first time a study numbered the ones at risk. In the United States, about 8.6 percent of the population—or some 25 million people—were diagnosed with diabetes in 2010, based on prior Bloomberg News data. That number is expected to rise to more than 34 million by 2020.

Need Legal Help Regarding Merck’s Januvia?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Excellent Company! I am part of the Roundup class action suit and have been very impressed. Lisa Perez is my contact person, she is amazing!!!
Don Torchia
a year ago
5 Star Reviews 150
About 7 years ago, my sister was in a car accident and was very pleased with the way the firm handled her case. Unforuntately, I was in a car accident and she recommended that I call Parker Waichman. I could not be more happy with the way the case was handled and the outcome. The staff is also very friendly, which was refreshing.
Paul Schaeffer
11 years ago
5 Star Reviews 150
Michelle Josama it was a pleasure To work with You are the Best at what You do.Thank you so much for everything you did an amazing job For our family. Chuck Silverstein we were very lucky To have you as our lawyer you did An amazing job and we appreciate you Thank you so much we will highly Recommend you to our friends and family.
Will bivens
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038